

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.



邁博藥業
Mabpharm Limited
迈博药业有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2181)

**SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO
THE POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON
FRIDAY, JUNE 17, 2022**

Reference is made to the poll results of the annual general meeting held on June 17, 2022 (the “**Poll results**”) of Mabpharm Limited (the “**Company**”) dated June 17, 2022. Unless otherwise stated, terms used in this announcement shall have the same meanings as those defined in the Poll results.

This announcement is made pursuant to Rule 13.39(5A) of the Listing Rules to provide supplemental information on the attendance of the Directors at the AGM.

The AGM was chaired by Mr. Li Yunfeng, executive Director of the Company. Executive Directors Dr. Wang Hao and Dr. Li Jing attended the AGM in person, executive Director Mr. Tao Jing, non-executive Directors Mr. Jiao Shuge and Mr. Guo Jianjun and independent non-executive Directors Mr. Guo Liangzhong, Dr. Zhang Yanyun and Dr. Liu Linqing attended the AGM by electronic means.

By Order of the Board
Mabpharm Limited
Jiao Shuge
Chairman

Hong Kong, June 21, 2022

As at the date of this announcement, the Board of Directors comprises Dr. Wang Hao, Mr. Tao Jing, Mr. Li Yunfeng, and Dr. Li Jing as executive Directors; Mr. Jiao Shuge and Mr. Guo Jianjun as non-executive Directors; and Mr. Guo Liangzhong, Dr. Zhang Yanyun and Mr. Leung, Louis Ho Ming as independent non-executive Directors.